Ketamine Trial for the Treatment of Depression

Randomised, triple-masked, parallel-group Phase I study enrolling 10 participants with major depressive disorder (MADRS ≥ 20) and prior inadequate response to at least two antidepressants to compare ketamine with placebo.

Primary purpose is treatment; outcomes and safety assessments follow trial protocol. Eligible and exclusion criteria address psychiatric history, suicide risk, substance use, and contraindications to ketamine.